Harlan Robins Sells Shares of Adaptive Biotechnologies
Harlan Robins, Chief Scientific Officer, sold 6,160 shares of Adaptive Biotechnologies.
Key Points
- Harlan Robins sold 6,160 shares of Adaptive Biotechnologies for $110,941.6 on June 16, 2026.
- Shares of ADPT traded at $17.07 with a market cap of $2.76 billion; the company is not currently profitable.
- Viking Global holds 29.99 million shares, while BlackRock reduced its stake by 30,534 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Harlan Robins, the Chief Scientific Officer of Adaptive Biotechnologies Corporation, sold 6,160 shares of the company on June 16, 2026. The shares were sold at an average price of $18.01, amounting to a total transaction value of approximately $110,941.6. This sale was conducted under a pre-planned trading program.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
In addition to Harlan Robins' recent sale, there have been other insider transactions at Adaptive Biotechnologies. Robins sold 100,000 shares on June 15, 2026, at $17.37 per share. Susan Bobulsky, Chief Commercial Officer, MRD, sold 5,000 shares on June 11, 2026, at $19.00 each. Francis Lo, Chief People Officer, had multiple transactions on June 4, 2026, including a sale of 39,741 shares at $17.49 under a planned program.
Other Institutional Activity in Adaptive Biotechnologies
Viking Global Investors LP holds a substantial position in Adaptive Biotechnologies, with 29,993,708 shares valued at about $416.31 million, with no recent change in their holdings. BlackRock, Inc. trimmed its position slightly by 30,534 shares, ending with 13,303,025 shares worth approximately $184.65 million. Vanguard Capital Management LLC added 6,094,144 shares, bringing its total to the same number, valued at $84.59 million. Westfield Capital Management Co LP increased its stake by 1,376,237 shares, holding 5,436,718 shares valued at about $75.46 million.
Adaptive Biotechnologies Corporation Stock Down 31.7%
Shares of NasdaqGS:ADPT traded near $17.07. The company has a market capitalization of approximately $2.76 billion. It is not currently profitable, as indicated by its negative forward P/E ratio of -68.10. The stock has experienced a 52-week low of $9.96 and a high of $20.76. Its 50-day moving average stands at $14.69, with a 200-day moving average of $15.42. The company has a beta of 2.151, reflecting higher volatility, and maintains a current ratio of 3.35, with a quick ratio of 3.08. Its debt-to-equity ratio is 92.84.
$ADPT stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Adaptive Biotechnologies reported revenue of $295.41 million, reflecting a growth of 35.1%. However, the company posted a net margin of -16.82% and a return on equity of -23.96%. The next earnings report is scheduled for August 4, 2026.
Analysts Set New Price Targets
On May 12, 2026, Morgan Stanley maintained a 'hold' rating with an $18.00 price target. JP Morgan and TD Cowen both maintained 'buy' ratings on May 6, 2026, with targets of $19.00 and $21.00, respectively. The consensus among analysts is a 'strong buy' with a mean target price of $20.14, based on seven opinions.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, headquartered in Seattle, Washington, operates in the healthcare sector, focusing on diagnostics and research. The company has developed an immune medicine platform that aids in diagnosing and treating various diseases. Its clonoSEQ test is notable for detecting minimal residual disease in cancer patients. Led by CEO Chad M. Robins, the company employs 624 people.
Bottom Line
Harlan Robins' planned sale of shares highlights ongoing insider activity at Adaptive Biotechnologies. The company's stock has shown volatility, with a recent trading price near $17.07. Institutional investors like Viking Global and BlackRock have significant stakes, reflecting interest in the company's potential. As always, remember that insider transactions and 13F filings are backward-looking and may not represent current positions.
Get Adaptive Biotechnologies Corporation alerts
New 13F filings, insider trades, and analyst moves on $ADPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.